$BTMD: Biote Corp. - Class A common stock

Biote Corp. (NASDAQ: BTMD) is a clinical-stage biotechnology company focused on developing and commercializing its proprietary Biote Method for the treatment of autoimmune and inflammatory diseases. The Biote Method is a personalized, biologic therapy that uses the patient's own immune cells to treat the underlying cause of the disease.

Biote was founded in 2012 by Dr. Michael J. Smith, a physician and researcher who has over 30 years of experience in the field of immunology. The company is headquartered in San Diego, California, and has a state-of-the-art training facility where physicians, healthcare providers, and medical staff members are trained in the Biote Method.

The Biote Method is based on the principle that autoimmune and inflammatory diseases are caused by an imbalance in the immune system. The therapy works by extracting the patient's own immune cells, called T cells, and then stimulating them in the laboratory to become more effective at fighting the disease. The activated T cells are then returned to the patient, where they help to restore the balance of the immune system.

Biote has completed two Phase 2 clinical trials of the Biote Method for the treatment of rheumatoid arthritis. The trials showed that the therapy was safe and effective, and that it led to significant improvements in symptoms and quality of life. Biote is currently conducting a Phase 3 clinical trial of the Biote Method for the treatment of rheumatoid arthritis, and it is also planning to initiate clinical trials for the treatment of other autoimmune and inflammatory diseases.

The Biote Method has the potential to be a breakthrough therapy for autoimmune and inflammatory diseases. The therapy is safe and effective, and it has the potential to provide long-term relief from symptoms. Biote is a well-funded company with a strong management team, and it is well-positioned to bring the Biote Method to market.

In addition to the Biote Method, Biote is also developing other products based on its proprietary technology. These products include a therapy for the treatment of psoriasis, a therapy for the treatment of Crohn's disease, and a therapy for the treatment of ulcerative colitis. Biote is also developing a diagnostic test that can be used to identify patients who are likely to benefit from the Biote Method.

Biote is a promising biotechnology company with the potential to make a significant impact on the treatment of autoimmune and inflammatory diseases. The company has a strong management team, a well-funded pipeline of products, and a proprietary technology that has the potential to revolutionize the treatment of these diseases.